<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="692">
  <stage>Registered</stage>
  <submitdate>6/09/2005</submitdate>
  <approvaldate>6/09/2005</approvaldate>
  <nctid>NCT00148356</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of the ZoMaxx Drug-Eluting Stent System in Coronary Arteries</studytitle>
    <scientifictitle>A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System Compared to the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in de Novo Coronary Artery Lesions</scientifictitle>
    <utrn />
    <trialacronym>ZoMaxx™ I</trialacronym>
    <secondaryid>640-0047</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Disease</healthcondition>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <healthcondition>Coronary Restenosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - ZoMaxx Drug-Eluting Coronary Stent System
Treatment: devices - TAXUS EXPRESS2 Paclitaxel Eluting Coronary Stent System

Experimental: 1 - ZoMaxx Drug-Eluting Stent System

Active Comparator: 2 - TAXUS EXPRESS2 Paclitaxel Eluting Coronary Stent System


Treatment: devices: ZoMaxx Drug-Eluting Coronary Stent System
Drug eluting stent implantation stent in the treatment of coronary artery disease.

Treatment: devices: TAXUS EXPRESS2 Paclitaxel Eluting Coronary Stent System
Drug eluting stent implantation stent in the treatment of coronary artery disease.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary end-point is in-segment late-loss at 9 months (as measured by QCA), defined as the difference between the post-procedure minimal lumen diameter (MLD) and the follow-up angiography MLD.</outcome>
      <timepoint>9 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Target Lesion revascularization(TLR)</outcome>
      <timepoint>at 9 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Revascularization (TVR)</outcome>
      <timepoint>at 9 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Target Vessel Failure</outcome>
      <timepoint>at 9 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major Adverse Cardiac Events(MACE) defined as Cardiac Death, MI( Q-wave and non Q-wave) or TVR</outcome>
      <timepoint>at 30 days, 6,9,12 months and anually through 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria include all of the following:

          -  Subject is = 18 years old.

          -  Female of childbearing potential must have a negative pregnancy test within 7 days
             prior to enrollment and utilize reliable birth control for nine (9) months after
             enrollment.

          -  Subject is eligible for percutaneous coronary intervention (PCI) and has a single
             lesion requiring treatment.

          -  Subject is an acceptable candidate for CABG.

          -  Subject has clinical evidence of ischemic heart disease or a positive functional
             study.

          -  Subject has documented stable angina pectoris</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria include all of the following:

          -  Evidence of an acute myocardial infarction (AMI) or CK-MB &gt; 2x upper limit of normal
             within 72 hours of the intended treatment (refer to WHO definition).

          -  Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®) or
             ticlopidine (Ticlid®), heparin, stainless steel, tantalum, contrast agent (that cannot
             be adequately premedicated), paclitaxel, or drugs similar to ABT-578 (i.e. tacrolimus,
             sirolimus, everolimus).

          -  A platelet count &lt; 100 x 109/L or &gt; 700 x 109/L (&lt; 100,000 cells/mm3 or &gt; 700,000
             cells/mm3); a WBC &lt; 3,000 cells/mm3; or a hemoglobin &lt; 10.0 g/dl.

          -  Acute or chronic renal dysfunction (creatinine &gt; 2.0 mg/dl or &gt; 150 µmol/L).

          -  Subject has had any previous or planned brachytherapy in the target vessel.

          -  Target vessel has evidence of thrombus or is excessively tortuous (&gt; 60 degree bend)
             that makes it unsuitable for proper stent delivery and deployment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>401</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>St. Vincent's Hospital - Fitzroy</hospital>
    <hospital>Monash Medical Center - Victoria</hospital>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3168 - Victoria</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Aalst</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liège</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Århus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Ollioules</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-Denis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse, Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Krozingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dortmund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Siegburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Carnaxide</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Kreuzlingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Meyrin-Geneva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zürich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Abbott Vascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx
      drug-eluting stent in patients with blockage of native coronary arteries. The study is
      designed to demonstrate non-inferiority to the TAXUS Express2 Paclitaxel-Eluting Stent that
      has proven superior to bare metal stents and is a recognized standard of care.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00148356</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bernard Chevalier, M.D.</name>
      <address>Centre Cardiologique du Nord</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>